<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DESMOPRESSIN ACETATE</span><br/>(des-moe-pres'sin)<br/><span class="topboxtradename">DDAVP, </span><span class="topboxtradename">Stimate<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">pituitary (antidiuretic) hormone</span><br/><b>Prototype: </b>Vasopressin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.1 mg, 0.2 mg tablets; 0.1 mg/mL, 1.5 mg/mL nasal solution; 4 mcg/mL, 15 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic analog of the natural human posterior pituitary (antidiuretic) hormone, arginine vasopressin. Has more specific
         and longer duration of action than antidiuretic hormone and lower incidence of allergic reactions. Also, oxytocic and vasopressor
         actions are not apparent at therapeutic dosages. Unlike vasopressin, it does not stimulate release of adrenocorticotropic
         hormone nor does it increase plasma cortisol, growth hormone, prolactin, or luteinizing hormone levels.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces urine volume and osmolality in patients with central diabetes insipidus by increasing reabsorption of water by kidney
         collecting tubules. Produces a dose-related increase in factor VIII (antihemophilic factor) and von Willebrand's factor.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To control and prevent symptoms and complications of central (neurohypophyseal) diabetes insipidus, and to relieve temporary
         polyuria and polydipsia associated with trauma or surgery in the pituitary region.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To increase factor VIII activity in selected patients with mild to moderate hemophilia A and in type I von Willebrand's disease
         or uremia, and to control enuresis in children.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Nephrogenic diabetes insipidus, type II B von Willebrand's disease. Safe use during pregnancy (category B) or lactation is
         not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Coronary artery insufficiency, hypertensive cardiovascular disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes Insipidus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Intranasal</span> 0.10.4 mL (1040 mcg) in 13 divided doses <span class="rdroute">IV/SC</span> 24 mcg in 2 divided doses <span class="rdroute">PO</span> 0.20.4 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span> <i>3 mo12 y</i>, 0.050.3 mL in 12 divided doses <span class="rdroute">IV/SC</span> 0.3 mcg/kg infused over 1530 min <span class="rdroute">PO</span> 0.05 mg titrated to response <br/><br/><span class="indicationtitle">Enuresis</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Intranasal</span> 540 mcg h.s.<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/>6 <i>y</i>, 0.2 mg h.s., may titrate up to 0.6 mg h.s.<br/><br/><span class="indicationtitle">Von Willebrand's Disease</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">IV/SC</span> &gt;<i>3 mo</i>, 0.3 mcg/kg 30 min preop, may repeat in 48 h if needed<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Note that 0.2 mg PO is equivalent to 10 mcg (0.1 mL) intranasal.</li>
</ul><span class="adminroutetype">Intranasal</span><br/><ul>
<li>Follow manufacturer's instructions for proper technique with nasal spray.</li>
<li>Give initial dose in the evening, and observe antidiuretic effect. Dose is increased each evening until uninterrupted sleep
            is obtained. If daily urine volume is more than 2 L after nocturia is controlled, morning dose is started and adjusted daily
            until urine volume does not exceed 1.52 L/24 h.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted for diabetes insipidus.  <span class="methodtype"> IV Infusion:</span> Dilute 0.3 mcg/kg in 10 mL of NS (children <img src="../images/special/lesserorequal.gif"/>10 kg) or 50 mL of NS (children
                  &gt;10 kg and adults) for von Willebrand's disease (type I).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give direct IV over 30 s for diabetes insipidus.  <span class="methodtype">IV Infusion:</span> Give over 1530 min for von Willebrand's disease (type I).  
               </p>
</td>
</tr>
</table>
<ul>
<li>Store parenteral and nasal solution in refrigerator preferably at 4° C (39.2° F) unless otherwise directed. Avoid
            freezing. 
         </li>
<li>Nasal spray can be stored at room temperature.</li>
<li>Discard solutions that are discolored or contain particulate matter.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">All:</span> Dose related. <span class="typehead">CNS:</span> Transient headache, drowsiness, listlessness. <span class="typehead">Special Senses:</span> Nasal congestion, rhinitis, nasal irritation. <span class="typehead">GI:</span> Nausea, heartburn, mild abdominal cramps. <span class="typehead">Other:</span> Vulval pain, shortness of breath, slight rise in BP, facial flushing, pain and swelling at injection site. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Demeclocycline,</b>
<b>lithium,</b> other <span class="classification">vasopressors</span> may decrease antidiuretic response; <b>carbamazepine,</b>
<b>chlorpropamide,</b>
<b>clofibrate</b> may prolong antidiuretic response. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1020% absorbed through nasal mucosa. <span class="typehead">Onset:</span> 1560 min. <span class="typehead">Peak:</span> 15 h. <span class="typehead">Duration:</span> 521 h. <span class="typehead">Distribution:</span> Small amount crosses bloodbrain barrier; distributed into breast milk. <span class="typehead">Half-Life:</span> 76 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor I&amp;O ratio and pattern (intervals). Fluid intake must be carefully controlled, particularly in older adults and the
            very young to avoid water retention and sodium depletion.
         </li>
<li>Weigh patient daily and observe for edema. Severe water retention may require reduction in dosage and use of a diuretic.</li>
<li>Monitor BP during dosage-regulating period and whenever drug is administered parenterally.</li>
<li>Monitor urine and plasma osmolality. An increase in urine osmolality and a decrease in plasma osmolality indicate effectiveness
            of treatment in diabetes insipidus.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report upper respiratory tract infection or nasal congestion.</li>
<li>Follow manufacturer's instructions for insertion to ensure delivery of drug high into nasal cavity and not down throat. A
            flexible calibrated plastic tube is provided.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>